Browse

Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis

DC Field Value Language
dc.contributor.authorLee, Seon Heui-
dc.contributor.authorHong, Jin Hyuk-
dc.contributor.authorCho, Kyoung Hee-
dc.contributor.authorNoh, Jin-Won-
dc.contributor.authorCho, Hyun-Jai-
dc.date.accessioned2017-03-23T07:15:32Z-
dc.date.available2017-03-23T17:03:05Z-
dc.date.issued2016-10-20-
dc.identifier.citationStem Cell Research & Therapy, 7(1):153ko_KR
dc.identifier.urihttps://hdl.handle.net/10371/109958-
dc.description.abstractBackground
Bone marrow-derived cell therapy has been used to treat acute myocardial infarction. However, the therapeutic efficacy of this approach remains controversial. Here, we performed a systematic review and meta-analysis to evaluate short-term and long-term effectiveness of bone marrow-derived therapy.

Methods
We searched eight databases (Ovid-Medline, Ovid-EMBASE, Cochrane Library, KoreaMed, KMBASE, KISS, RISS, and KisTi) up to December 2014. Demographic characteristics, clinical outcomes, and adverse events were analyzed. We identified 5534 potentially relevant studies; 405 were subjected to a full-text review. Forty-three studies with 2635 patients were included in this review.

Results
No safety issues related to cell injection were reported during follow-up. At 6 months, cell-injected patients showed modest improvements in left ventricular ejection fraction (LVEF) compared with the control group. However, there were no differences between groups at other time points. In the cardiac MRI analysis, there were no significant differences in infarct size reduction between groups. Interestingly, mortality tended to be reduced at the 3-year follow-up, and at the 5-year follow-up, cell injection significantly decreased all-cause mortality.

Conclusions
This meta-analysis demonstrated discrepancies between short-term LV functional improvement and long-term all-cause mortality. Future clinical trials should include long-term follow-up outcomes to validate the therapeutic efficacy of cell therapy.
ko_KR
dc.language.isoenko_KR
dc.publisherBioMed Centralko_KR
dc.subjectCell therapyko_KR
dc.subjectAcute myocardial infarctionko_KR
dc.subjectSurvivalko_KR
dc.subjectBone marrowko_KR
dc.titleDiscrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이선희-
dc.contributor.AlternativeAuthor홍진혁-
dc.contributor.AlternativeAuthor조경희-
dc.contributor.AlternativeAuthor노진원-
dc.contributor.AlternativeAuthor조현재-
dc.identifier.doi10.1186/s13287-016-0415-z-
dc.language.rfc3066en-
dc.rights.holderThe Author(s).-
dc.date.updated2017-01-06T10:50:55Z-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Thoracic Surgery (흉부외과학전공)Journal Papers (저널논문_흉부외과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse